Abstract
Investment in biomedical
innovation today represents one of the most high value areas of investment
economies can secure. In 2014 global life sciences R&D spending was
estimated at around $200 billion, with investment by leading research-based biopharmaceutical companies at over
a quarter of this figure. Today, economies seeking to attract biomedical
investment are competing on a global scale, with developed and emerging
economies vying for this investment side
by side. But how do governments and economies improve their
competitiveness and secure a
larger piece of global biomedical investment? A growing body of data suggests
that on top of market size, demand and costs, economies’ competitiveness
for biomedical investment is positively linked to the local policy
environment – all of the laws, regulations and
initiatives in place affecting biopharmaceuticals. Thus, for developed
and emerging economies alike that
have targeted biomedical investment as being of strategic importance to
national economic development and
growth, there is a pressing need to understand and map the state of
the biomedical investment environment in a given economy.
| Original language | English |
|---|---|
| Place of Publication | Washington DC |
| Publisher | Pugatch Consilium |
| Commissioning body | PhRMA |
| Number of pages | 86 |
| Edition | 2 |
| State | Published - 2015 |